共 44 条
- [41] Phase II study of primary systemic therapy (PST) with doxorubicin (D) and docetaxel (T), then surgery (S), and radiation (RT), followed by use of non-cross-resistant adjuvant chemotherapy (Adj CT) with CMF based on pathologic response, in patients (pts) with locally advanced breast cancer (LABC): Long-term results from study ID97-099, M. D. Anderson Cancer CenterJOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)Alvarez, R. H.Kau, S.Strom, E. A.Sahin, A. A.Singletary, S. E.Booser, D. J.Cristofanilli, M.Esteva, F. J.Hortobagyi, G. N.Valero, V.
- [42] SWOG S1418/NRG-BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with ≥ 1 cm residual invasive cancer or positive lymph nodes (>pN1mic) after neoadjuvant chemotherapyCANCER RESEARCH, 2018, 78 (04)Pusztai, LajosBarlow, William E.Ganz, Patricia A.Henry, Norah L.White, JuliaJagsi, ReshmaMammen, Joshu M. V.Lew, DanikaMejia, JaimeKarantza, VassilikiAktan, GurselSharon, EladKorde, LarissaHortobagyi, Gabriel N.Mamounas, Eleftherios
- [43] Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) ≤ 25 randomized to endocrine therapy (ET) plus /- chemotherapy (CT): SWOG S1007 (RxPONDER)CANCER RESEARCH, 2022, 82 (04)Kalinsky, Kevin M.Barlow, William E.Gralow, Julie R.Meric-Bernstam, FundaAlbain, Kathy S.Hayes, Daniel F.Lin, Nancy U.Perez, Edith A.Goldstein, Lori A.Chia, Stephen K. L.Dhesy-Thind, SukhbinderRastogi, PriyaAlba, EmilioDelaloge, SuzetteMartin, MiguelKelly, Catherine M.Ruiz-Borrego, ManuelGil-Gil, MiguelArce-Salinas, Claudia H.Brain, Etienne G. C.Lee, Eun SookPierga, Jean-YvesBermejo, BegonaRamos-Vasquez, ManuelJung, Kyung HaeFerrero, Jean-MarcSchott, AnneShak, StevenSharma, PriyankaLew, DanikaMiao, JielingTripathy, DebasishPusztai, LajosHortobagyi, Gabriel
- [44] Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER22-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)El Saghir, Nagi S.Yap, Yoon SimEralp, YesimIm, Seock-AhAzim, Hamdy A.Rihani, JulieVolkov, NikitaChen, Shin-ChehHarputluoglu, HakanSunpaweravong, PatrapimChang, Yuan-ChingAlfaro, Teresa DelgarWu, JiwenHu, HuilinGao, MingLu, Yen-Shen